Analysts Give These Stocks Mix Nod: Rio Tinto plc (RIO), Portola Pharmaceuticals, Inc. (PTLA)

Rio Tinto plc (NYSE:RIO) recorded a trading volume of 1.93 million shares, below its 90-day volume average of 2.56 million shares. The stock kicked off the session at $47.55 and later approached $47.59 with a change of -0.08%.

Rio Tinto plc (RIO) Analyst Opinion

Rio Tinto plc has a consensus outperform rating from 7 Wall Street analysts, and the number of shares currently sold short amount to at least 1.2% of shares outstanding. The stock sank -1.12% last month and is up 23.74 this year. Wall Street is only getting more bullish on the stock, with 6 of analysts who cover RIO having a buy-equivalent rating. Analysts have placed a $55.6 price target on Rio Tinto plc, suggesting a 16.83% gain from recent close. It’s currently trading about -6.26% below its 52-week high.

Rio Tinto plc (NYSE:RIO) Intraday View

This stock (RIO) is ahead of its 52-week low with 31.28%. Its last month’s stock price volatility remained 1.47% which for the week stands at 1.4%. The share price has moved backward from its 20 days moving average, trading at a distance of -1.97% and stays -1.6% away from its 50 days moving average. Over the last five days, shares have faced -3.88% losses and now is up 8.12% since hitting its 200-day moving average of $45.01. Rio Tinto plc (RIO) has made its way to a 12-month gain of 26.7%.

Turning to Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), its shares were trading at $49.28 a gain of $0.13, on the trading floor. The stock, after opening at $49, touched a high of $49.5 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.5. Portola Pharmaceuticals, Inc. has 3 buy ratings, 0 holds and 0 sells even after the stock tumbled -26.56% from its high of $67.10 to a $3.07 billion market value through last close.

Portola Pharmaceuticals, Inc. (PTLA) Consensus Price Target

The company’s consensus rating on Reuter’s scale slipped from 1.6 to 1.5 during a month. Analysts set a 12-month price target of $75.4 a share. The target implies a 53% spike from where the shares are currently trading. Also, the current price highlights a discount of 62.34% to analysts’ high consensus price target.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Intraday Trading

The counter witnessed a trading volume of 0.34 million shares versus an average volume of 0.91 million shares during last trading session. Its last month’s stock price volatility remained 3.17% which for the week approaches 3.95%. The lowest price the stock reached in the last trading day was $48.57 and compares with the $17.15 52-week low. The stock recovered 187.35% since its low point and has performed 119.61% year-to-date.

Previous articleHot Stocks Report: Crown Castle International Corp. (REIT) (CCI), Juno Therapeutics, Inc. (JUNO)
Next articleAnalysts Are Gushing Over EOG Resources, Inc. (EOG), AveXis, Inc. (AVXS)